By integrating chemerin measurement into clinical practise, healthcare providers could better identify patients at higher risk of plaque instability, allowing for more proactive management strategies aimed at preventing plaque rupture and subsequent myocardial infarction. The gene discussed is RARRES2; the disease is myocardial infarction.